185 related articles for article (PubMed ID: 21481923)
1. An assay to evaluate heparanase procoagulant activity.
Nadir Y; Kenig Y; Drugan A; Shafat I; Brenner B
Thromb Res; 2011 Oct; 128(4):e3-8. PubMed ID: 21481923
[TBL] [Abstract][Full Text] [Related]
2. Increased heparanase level and procoagulant activity in orthopedic surgery patients receiving prophylactic dose of enoxaparin.
Peled E; Rovitsky A; Axelman E; Norman D; Brenner B; Nadir Y
Thromb Res; 2012 Jul; 130(1):129-34. PubMed ID: 22154361
[TBL] [Abstract][Full Text] [Related]
3. Heparanase procoagulant activity.
Nadir Y; Brenner B
Thromb Res; 2012 Apr; 129 Suppl 1():S76-9. PubMed ID: 22682139
[TBL] [Abstract][Full Text] [Related]
4. Heparanase procoagulant activity is elevated in women using oral contraceptives.
Matan M; Axelman E; Brenner B; Nadir Y
Hum Reprod; 2013 Sep; 28(9):2372-80. PubMed ID: 23800622
[TBL] [Abstract][Full Text] [Related]
5. Heparanase procoagulant activity, factor Xa, and plasminogen activator inhibitor 1 are increased in shift work female nurses.
Nadir Y; Saharov G; Hoffman R; Keren-Politansky A; Tzoran I; Brenner B; Shochat T
Ann Hematol; 2015 Jul; 94(7):1213-9. PubMed ID: 25743687
[TBL] [Abstract][Full Text] [Related]
6. Involvement of heparanase in vaginal and cesarean section deliveries.
Nadir Y; Kenig Y; Drugan A; Zcharia E; Brenner B
Thromb Res; 2010 Dec; 126(6):e444-50. PubMed ID: 20932554
[TBL] [Abstract][Full Text] [Related]
7. Heparanase procoagulant activity is elevated and predicts survival in non-small cell lung cancer patients.
Nadir Y; Sarig G; Axelman E; Meir A; Wollner M; Shafat I; Hoffman R; Brenner B; Vlodavsky I; Haim N
Thromb Res; 2014 Sep; 134(3):639-42. PubMed ID: 25065557
[TBL] [Abstract][Full Text] [Related]
8. Heparanase procoagulant effects and inhibition by heparins.
Nadir Y; Brenner B
Thromb Res; 2010 Apr; 125 Suppl 2():S72-6. PubMed ID: 20434010
[TBL] [Abstract][Full Text] [Related]
9. Novel peptides that inhibit heparanase activation of the coagulation system.
Axelman E; Henig I; Crispel Y; Attias J; Li JP; Brenner B; Vlodavsky I; Nadir Y
Thromb Haemost; 2014 Sep; 112(3):466-77. PubMed ID: 25030319
[TBL] [Abstract][Full Text] [Related]
10. Heparanase induces tissue factor pathway inhibitor expression and extracellular accumulation in endothelial and tumor cells.
Nadir Y; Brenner B; Gingis-Velitski S; Levy-Adam F; Ilan N; Zcharia E; Nadir E; Vlodavsky I
Thromb Haemost; 2008 Jan; 99(1):133-41. PubMed ID: 18217145
[TBL] [Abstract][Full Text] [Related]
11. Heparanase coagulation and cancer progression.
Nadir Y; Brenner B
Best Pract Res Clin Haematol; 2009 Mar; 22(1):85-92. PubMed ID: 19285275
[TBL] [Abstract][Full Text] [Related]
12. Heparanase, tissue factor, and cancer.
Nadir Y; Vlodavsky I; Brenner B
Semin Thromb Hemost; 2008 Mar; 34(2):187-94. PubMed ID: 18645924
[TBL] [Abstract][Full Text] [Related]
13. Heparanase procoagulant activity in cancer progression.
Nadir Y; Brenner B
Thromb Res; 2016 Apr; 140 Suppl 1():S44-8. PubMed ID: 27067977
[TBL] [Abstract][Full Text] [Related]
14. Progesterone utilizes distinct membrane pools of tissue factor to increase coagulation and invasion and these effects are inhibited by TFPI.
Henriquez S; Calderon C; Quezada M; Oliva B; Bravo ML; Aranda E; Kato S; Cuello MA; Gutiérrez J; Quest AF; Owen GI
J Cell Physiol; 2011 Dec; 226(12):3278-85. PubMed ID: 21344386
[TBL] [Abstract][Full Text] [Related]
15. Heparanase enhances the generation of activated factor X in the presence of tissue factor and activated factor VII.
Nadir Y; Brenner B; Fux L; Shafat I; Attias J; Vlodavsky I
Haematologica; 2010 Nov; 95(11):1927-34. PubMed ID: 20634491
[TBL] [Abstract][Full Text] [Related]
16. Microparticles (MPs), tissue factor (TF) and tissue factor inhibitor (TFPI) in cord blood plasma. A preliminary study and literature survey of procoagulant properties of MPs.
Uszyński M; Zekanowska E; Uszyński W; Kuczyński J; Zyliński A
Eur J Obstet Gynecol Reprod Biol; 2011 Sep; 158(1):37-41. PubMed ID: 21664032
[TBL] [Abstract][Full Text] [Related]
17. Heparanase level and procoagulant activity are reduced in severe sepsis.
Matan M; King D; Peled E; Ackerman S; Bar-Lavi Y; Brenner B; Nadir Y
Eur J Haematol; 2018 Feb; 100(2):182-188. PubMed ID: 29120525
[TBL] [Abstract][Full Text] [Related]
18. Involvement of the heparanase procoagulant domain in bleeding and wound healing.
Crispel Y; Ghanem S; Attias J; Kogan I; Brenner B; Nadir Y
J Thromb Haemost; 2017 Jul; 15(7):1463-1472. PubMed ID: 28439967
[TBL] [Abstract][Full Text] [Related]
19. Tissue factor procoagulant activity of plasma microparticles is increased in patients with early-stage prostate cancer.
Haubold K; Rink M; Spath B; Friedrich M; Chun FK; Marx G; Amirkhosravi A; Francis JL; Bokemeyer C; Eifrig B; Langer F
Thromb Haemost; 2009 Jun; 101(6):1147-55. PubMed ID: 19492160
[TBL] [Abstract][Full Text] [Related]
20. The relationship between plasma and placental tissue factor, and tissue factor pathway inhibitors in severe pre-eclampsia patients.
Teng Y; Jiang R; Lin Q; Ding C; Ye Z
Thromb Res; 2010 Jul; 126(1):e41-5. PubMed ID: 20226500
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
